Compare ARK Genomic Revolution ETF (ARKG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Merck & Co., Inc. — how do they compare? ARK Genomic Revolution ETF trades at $51.16 (market cap $1.56B), while Merck & Co., Inc. trades at $146.22 (market cap $363.04B). The key difference: Merck & Co., Inc. is far larger — about 232.7× ARK Genomic Revolution ETF's market cap, and Merck & Co., Inc. pays a 2.31% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ARK Genomic Revolution ETF for 30 Days and Merck & Co., Inc. for 98 Days on average.
| ARKG | MRK | |
|---|---|---|
Market Cap | $1.56B | $363.04B |
Volume | 8,568,284 | 9,546,313 |
Sector | Sector/Thematic | Health |
52-Week High | $51.47 | $156.43 |
52-Week Low | $24.82 | $77.60 |
Typical Hold Time | 30 Days | 98 Days |
Enterprise Value | — | $409.81B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MRK trades at $144.95, up 0.8% on the day, with a bullish technical signal and strong institutional interest. Recent earnings have consistently beaten expectations, and the company is expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though valuation ratios such as a P/E of 117.72 are elevated.
The outlook is positive, supported by analyst consensus and strategic M&A, but risks include high debt levels and competitive pressures. The stock offers potential upside to the consensus price target of $158.12, yet investors should weigh the rich valuation against growth sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
